Key clinical point: Changes in LDL cholesterol were significantly greater in patients treated with evolocumab compared with controls after 4 weeks.
Major finding: From baseline to 4 weeks, LDL cholesterol levels decreased by an average of 76% in the evolocumab group vs. 33% in the control group (P < .001).
Study details: The data come from a prospective, open-label randomized trial of 102 adults in Japan who were treated for acute coronary syndrome at a single center.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Okada T et al. ESC 2020. JACC Cardiovasc Interv. 2020 Aug 28. doi: 10.1016/j.jcin.2020.08.026.